sensitive transcription factor nuclear factor -kB (NFkB) (5) and the prooxidant enzyme nitric oxide synthase (iNOS) (6, 7) , and induction of the antioxidant enzymes glutathione-S-transferases (8) could be related with the beneficial effects of green tea consumption against cancer (9, 10) . EGCG is the most potent catechin inhibiting cell growth in human lung and colon cancer cells (11) . In rat models EGCG has suppressed tumor growth in vitro in bladder (12) , breast (13), brain (14) and hepatic (15) cells, and inhibited bladder (12) , mammary (13) and colon (16) 
carcinogenesis in vivo.
Epidemiological studies in humans have suggested protective effects of green tea against esophageal, pancreatic, colorectal, gastric and breast cancer (10) . The biological properties of the green tea polyphenol including antioxidant actions, free radical scavenging, ironchelating properties, catechol-O-methytransferase activity reduction, kinase C or extracellular signal-regulated kinases signal pathway activation, and cell survival/cell cycle gene modulation, may benefit patients with Parkinson's disease (17) .
Previous reports showing the tissue distribution of EGCG in rats are scarce. EGCG has been determined in rat tissues after drinking 0.6% green tea polyphenols for 8 days (18) , and 60 minutes after giving it by stomach intubation at the high dose of 500 mg/kg in liver, brain, small intestinal and colon mucosa using complicated method of chemiluminiscence-high performance liquid chromatography (HPLC) detection (19) .
The purpose of our work is to study the antioxidant effect of EGCG after giving it orally at a concentration of 150 mg/kg body weight to rats and to determine the plasma and tissue levels of EGCG with developed by us electrochemical detector (ED)-HPLC detection method.
Experimental 1 Materials
Ascorbic acid, 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH) and ethanol were purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Acetonitrile, ethyl acetate, diethyl ether, hexane, 2-propanol and phosphoric acid were obtained from Kanto Chemical Co., Inc. (Tokyo, Japan). (+)-Catechin (C), (-)-epicatechin (EC), (-)-epigallocatechin (EGC), (-)-epigallocatechin gallate E-4143, minimum 95% (EGCG), b-glucuronidase G-7896 Type X-A from E. Coli with 1. 34 10 4 U/mg solid, and sulfatase S-9754
Type VIII from Abalone Entralis with 29 U/mg solid, were purchased from Sigma Chemical Co. (St. Louis, MO).
Animals and Diets
All experimental procedures were conducted in compliance with the Teikyo University's policy on animal care and use. Male, Sprague-Dawley strain, 5 wks old rats were purchased from Saitama Experimental Animals Supply Co. Ltd (Saitama, Japan). They were fed Certified-1 Diet (CRF-1) Oriental Yeast Co. (Tokyo, Japan) for 12 days before the experiment.
3 EGCG Administration to Rats and
Plasma and Tissues Collection The rats were fasted overnight before the experiment. For determining antioxidative activity of plasma, 6 rats were divided into three groups -control, 2 nd and 5 th hour, n=2 in each group. The rats weighed 190-220 g. EGCG was dissolved in distilled water at a concentration of 33 mg/mL immediately before the administration and a volume about 1 mL depending on the body weight was given perorally at a concentration of 150 mg/kg body weight to the rats anesthetized with diethyl ether. To control rats a volume of 1mL of physiological saline (0.15% NaCl) was given. At 2 nd and 5 th hour (n=2), and at the 24 th hour (n=4) a blood sample from the retroorbital plexus of each animal was taken into heparinized tubes (Venoject ® II, Terumo ® Corporation, Tokyo, Japan). The blood was centrifuged at 950 g for 10 min at 4 . The obtained pooled plasma from each group was subjected to oxidation immediately. The experiment was repeated twice.
For determining EGCG concentration in plasma and organs, EGCG was administered orally as described above to 2 groups of rats weighing 180 -210 g, n=4 in each group. At 2 nd and 5 th hour the rats were anesthetized with diethyl ether, and blood (5 mL) from the retroorbital plexus of each animal was taken into heparinized tubes. The blood was centrifuged at 950 g for 10 min at 4 and the resultant heparinized plasma was mixed with one-tenth of the volume with an ascorbic acid-Na 2 EDTA preservation solution [20% ascorbic acid and 0.01% Na 2 EDTA dissolved in 0. 4 
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ice-cold physiological saline. Then they were cut longitudinally and washed extensively. Tissues were stored at -80 until use.
4 Plasma Oxidation and a-Tocopherol
Extraction and Detection Pooled plasma (2 mL) was oxidized at 37 by 20 mM AAPH in a water bath shaker (150 oscillations per minute). Aliquots of 0.2 mL were withdrawn at measured time intervals. The oxidation was stopped by the addition of 100 mM of Na 2 EDTA and freezing (20) . aTocopherol was extracted as described previously (21) . It was detected by HPLC method with fluorescence detection, excitation wavelength of 298 nm and emission wavelength of 325 nm, Inertsil NH 2 -column, 4.6 150 mm, 5 mM (GL Sciences Inc., Tokyo, Japan), and a mobile phase of n-hexane/2-propanol (98:2, vol/vol ) at a flow rate of 0.5 mL/min.
5 Determination of Free and Total
EGCG in Plasma For the determination of the total EGCG containing free EGCG and EGCG glucuronides, sulfates and sulfate/glucuronides, to a volume of 550 mL of thawed plasma containing one-tenth of the volume ascorbic acid -Na 2 EDTA preservation solution, 500 ng of the internal standard C in 2% ascorbic acid, 0.01% Na 2 EDTA in 0.4 M phosphate buffer, final pH 3.7, and 20 mL (500 units) of b-glucuronidase solution in 0.4 M sodium phosphate buffer, pH 6.8, and 20 mL (20 units) of sulfatase solution in 0.1 M sodium acetate buffer, pH 5, were added. The mixture was incubated at 37 for 45 minutes (22) . For determination of the free EGCG the procedure of the addition of the enzymes was omitted. The reaction mixture was extracted three times with ethyl acetate (3 2 mL). The combined ethyl acetate layers were evaporated by N 2 stream. The residues were dissolved in 0.25 mL of 10% acetonitrile aqueous solution. The resultant solutions were centrifuged in a Centrifuge 5415-C (Eppendorf-NethelerHinz GmbH, Hamburg, Germany) at 12, 000 rpm for 3 minutes and filtered through 0.45 mM 4N disposable filter (Kurabo Industries Ltd., Osaka, Japan). A volume of 25 mL was injected onto the HPLC system. homogenized at ice by ultrasound in 1.6 mL distilled water containing 10% of ascorbic acid -Na 2 EDTA preservation solution. For prostate and bladder because of the low weight of the organs, the tissues of four rats were combined. The internal standard C was added at quantities of 2 mg for small intestine and colon, and 1 mg for the other tissues. The homogenates were centrifuged at 16,000 g for 5 min at 5 at TL-100 Ultracentrifuge (Beckman Instruments, Inc., Palo Alto, California). 1 mL of the supernatant was extracted twice by ethyl acetate (2 2.5 mL). The combined ethyl acetate layers were evaporated under N 2 and the residue was dissolved in 0.25 mL of 10% acetonitrile aqueous solution. The solutions were centrifuged at 12,000 rpm for 3 minutes at Eppendorf centrifuge and filtered through 0.45 mM 4N Kurabo disposable filter. For small intestine and colon 25 mL and for the other tissues 100 mL of the solutions were injected onto the HPLC system.
7 Standardization
Internal standard method was used. For calculating the EGCG concentration in plasma, to control plasma (0.55 mL, containing one tenth of the volume ascorbic acid -Na 2 EDTA preservation solution) were added 500 ng of the internal standard C, and EGCG in the range 45.84 -458.4 ng/mL. The EGCG spiked plasma further was analyzed as described. The recovery of EGCG from plasma samples was 88.6%. For calculating the EGCG concentrations in tissues a calibration curve of EGCG solution in 2% ascorbic acid, 0.01 % Na 2 EDTA in 0.4 M sodium phosphate buffer, final pH 3.7, in the range 10 -12 500 ng/mL was used. The detection limit was 10 ng/mL.
8 EGCG Determination by HPLC with
Electrochemical Detection For measuring EGCG concentration in plasma and tissues the HPLC system composed of pump PU 611, electrochemical detector ED-703 and Rheodyne injector (Rheodyne Incorporated, Cotati, CA) with a 100 mL loop were from GL Sciences Inc., Tokyo, Japan. The column ODS-3, 4.6 150 mm, 5 mM (GL Sciences Inc., Tokyo, Japan) was kept at a temperature of 30 into the detector oven. The mobile phase consisted of acetonitrile/ethyl acetate/0.05% phosphoric acid 
Results

1 Ex Vivo
Antioxidative Activity of Plasma of Rats Administered Orally 150 mg EGCG /kg Body Weight For evaluating the antioxidative activity of plasma, the percentage of the remaining a-tocopherol was compared after oxidizing plasma of rats that administered EGCG, and control plasma at 37 by 20 mM of the hydrophilic radical initiator AAPH. Plasma obtained from rat blood at 2 nd , 5 th and 24 th hours after EGCG administration showed antioxidative activity preserving a-tocopherol oxidation. The time course of a-tocopherol consumption is shown in Fig. 2 . a-Tocopherol was spared till 360 th minute of oxidation without changing the duration of the lag-phase at the 2 nd hour after EGCG administration. There was a significant increase in the lag-phase duration and a-tocopherol content was preserved during the whole course of oxidation at the 5 th hour. Even 24 hours after EGCG administration atocopherol was consumed in smaller extent than in control plasma in the initial phase of oxidation.
2 EGCG Quantification by HPLC with an
Electrochemical Detector We developed a method for measuring the concentration of EGCG and its metabolites in rat plasma using HPLC system with an electrochemical detector applying internal standard method. EGCG appeared at 14.8-14.9 minute and the internal standard C appeared at 7.4-7.5 minute as detected at the conditions described in the experimental part. The electrochemical spectrum after injecting of 100 mL of standard solution, containing 50 ng EGCG/mL and 500 ng C/mL is shown at Fig. 3A . In spiked control plasma C and EGCG appeared at the same time as in the standard solution as demonstrated in Fig. 3B . The peak that has appeared at 8.3-8.4 minute is unknown. The chromatograms after extracting free and total EGCG from the plasma of rat No. 3 at 2 nd hour are compared at Fig. 3C and Fig. 3D . At 12.1 minute unknown metabolite appeared in total EGCG chromatogram (Fig. 3D) (Fig. 3E) . EGC appeared at 5.2 minute, C -at 7.5 minute, EC -at 11.2 minute and EGCG -at 15 minute. Methylated EGCG was not detected.
Plasma Levels of EGCG
The levels of free and total EGCG, including free EGCG and EGCG glucuronides, sulfates and glucuronides/sulfates, in rat plasma are shown at Table 1 . For convenience the results are presented as ng/mL as well as mM. The total EGCG concentration diminished from 375.1 ng/mL (0.82 mM) at 2 nd hour to 227.4 ng/mL (0.5 mM) at the 5 th hour. We estimated previously the absorbed EGCG at 24 th hour in rat plasma to be 0.05 mM as detected by HPLC with an UV detector set at 280 nm (unpublished results). There was a significant variation in the EGCG and its metabolites levels because of the individual differences in absorption of EGCG. The largest portion of EGCG in rat plasma remained unconjugated. At 2 nd hour 85% of EGCG was present in the free form, and at the 5 th hour the content of the free EGCG was 56% from the total EGCG.
4 Tissue Levels of EGCG
The levels of free EGCG at 2 nd and 5 th hour after oral administration at a dose of 150 mg/kg body weight were determined in rat small intestine, colon, kidneys, liver, spleen, lung, and brain ( Table 2) . For convenience, to compare the data with previously published results in the literature, the levels of the absorbed EGCG were presented as ng/g as well as nmol/g. In 
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prostate and bladder the EGCG levels at 2 nd hour were determined to be 67.3 ng/g (0.15 nmol/g) and 163.4 ng/g (0.36 nmol/g), respectively. We measured only the free form of EGCG in tissues as previous reports showed that EGCG was presented only in the free form in small intestinal and colon mucosa in rats (19) or in the small intestine and liver in mice (23) after intragastrical administration.
The highest levels of free EGCG were found in the small intestine and in the colon. The decrease of the EGCG concentration in the small intestine and its increase in the colon were due to its movement from the colon to the intestine and absorption of EGCG from the small intestinal enterocytes to the portal circulation. The highest levels of EGCG were observed in the colon through which the unabsorbed EGCG was eliminated. In kidneys a smaller amount of EGCG was detected. A smaller quantity of EGCG was delivered out of the body through the urine. In liver, spleen, lung, and brain low quantities of EGCG were detected.
Discussion
We showed that 2, 5 and 24 hours after oral EGCG administration rat plasma had stronger antioxidant activity preserving a-tocopherol against ex vivo oxidation than control plasma. The plasma levels of total EGCG were estimated 0.82, 0.5 and 0.05 mM at 2 nd , 5 th and 24 th hour respectively. Aldini et al. (24) demonstrated that in vitro EGCG with IC 50 = 0.72 mM inhibited the aqueous compartment oxidation of human plasma induced by AAPH at the same concentration (20 mM), which we used, and spared the lipophilic antioxidants a-tocopherol and carotenoids. The increased antioxidant activity of plasma is due to the absorbed EGCG, its conjugates (glucuronides, sulfates and glucuronides/sulfates), and its final metabolites including the hydroxybenzoic acids. After oral administration of [4-(3) H] EGCG to rats the radioactivity in blood and most tissues remained low for 4 hours post dose, began to increase after 8 hours, peaked at 24 hours, and then decreased (25) . The authors showed that the radioactivity in blood mostly originated from degradation products of EGCG produced by intestinal bacteria. Pietta et al. (26) suggested that the final metabolites 3, 4-dihydroxybenzoic acid and vanillic acid mostly contributed to the measured increase of plasmatic total radical-trapping antioxidant parameter (TRAP) whereas the absorbed catechins, between which EGCG peaked at 2 nd hour with a concentration of 2 mM, contributed only 20% for the plasmatic TRAP increase in humans after ingesting of 400 mg of tea catechins. Taking into account the above investigations, we could explain the stronger antioxidant activity of plasma at 5 th hour than at the 2 nd hour, and the presence of antioxidant activity 24 hours after oral administration of EGCG (Fig. 2) .
The conjugated EGCG and methylated conjugated EGCG also contribute to the increased plasma antioxidant activity. EGCG is present as conjugates of glucuronate, sulfate or both of them, with or without methylation. It is known that after absorption, flavonoids are metabolized by the phase II drug metabolizing enzymes, the uridine-5'-diphosphate glucuronosyltransferases, sulfotransferases, and catechol-Omethyltransferases (27) . The small intestine is the organ primarily responsible for glucuronidation, but it also has a role in methylation. The major products of small intestine metabolism in the hepatic portal vein are glucuronides and perhaps methylated glucuronides. 
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conjugates may then gain access to hepatocytes and may be further methylated, glucuronidated, or sulfated in the liver (27, 28) . From hepatocytes the conjugates enter the blood and are transported to the other organs. Colonic microflora degrade the flavonoids into smaller phenolic acids that may also be absorbed in blood (28) . After oral administration of EGCG to rats the biliary metabolites found were EGCG, 3'-O-methyl-EGCG, 4'-O-methyl-EGCG, 3"-O-methyl-EGCG, 4"-Omethyl-EGCG, and 4', 4"-di-O-methyl-EGCG (29) . After giving 0.6% green tea polyphenol preparation as a drinking fluid to rats low levels of EGCG and 4', 4"-di-O-methyl-EGCG were detected in rat plasma, kidneys and liver, and higher -in small intestine (30) . 3"-Omethyl-EGCG and 4"-O-methyl-EGCG had similar antioxidant activities to EGCG (31, 32) whereas 4', 4"-di-O-methyl-EGCG had about one-tenth of the activities of EGCG (30) . EGCG-3'-O-glucuronide and EGCG-3"-O-glucuronide maintained similar potency as EGCG in scavenging the 1, 1-diphenyl-2-picrylhydrazyl (DPPH) radical, whereas EGCG-7-O-glucuronide and EGCG-4"-O-glucuronide were less active than EGCG, but more active than ascorbic acid (33) . Previously another study showed that after intragastric intubation of EC at doses of 50 mg/kg body weight and 250 mg/kg body weight the antioxidative ability of rat plasma was increased and a-tocopherol consumption in CuSO 4 oxidation was much lower than in control plasma (34) . The conjugated metabolites of EC were found to participate in the antioxidative defense of rat plasma (35) . The main metabolites in rat plasma and urine after EC administration were found to be 3'-O-methyl-EC, EC-7-O-glucuronide and 3'-O-methyl-EC-7-O-glucuronide (36). Harada et al. (37) found the main EC metabolites to be EC-5-O-glucuronide and 3'-Omethyl-EC-5-O-glucuronide. They showed that the glucuronides had the same activity as EC in scavenging superoxide anion radical while methylation at 3'-position decreased their activity two orders. The catechins EC and EGCG exhibited their antioxidant activity by the 3', 4'-orthodihydroxyl group in the B-ring. Methylation at 3"-or 4"-position did not affect the antioxidant activity whereas methylation of both 4'-and 4"-positions decreased the EGCG antioxidative activity similarly to EC where methylation at 3'-position diminished significantly its antioxidant potential. When the B-ring in EGCG was conjugated, it exhibited its antioxidative activity by the D-ring (33) .
We determined by HPLC with electrochemical detector the free EGCG in rat plasma to be 320 ng/mL at the 2 nd hour after administering orally about 30 mg EGCG/rat or 150 mg/kg body weight. Nakagawa and Miyazawa (38) found similar values 2 hours after administering by stomach intubation of 56 mg EGCG/rat using HPLC-chemiluminiscence detection and methanol extraction of EGCG. Chen et al. (39) giving EGCG to rats by intragastric intubation at a dose of 75 mg/kg body weight, twice smaller than the used by us, found the maximum EGCG concentration in rat plasma to be 19.8 ng/mL using coulochem electrode detection and ethyl acetate extraction of EGCG. Later the same group reported maximum levels of EGCG about 200 ng/mL achieved at the 15 th day after the rats were drinking 0.6% green tea polyphenol preparation (18) . Our results confirmed that EGCG was better absorbed in rats when given perorally compared to intragastric intubation. The same authors suggested that in the mice model EGCG was better absorbed than in the rat model. They found a peak plasma level in mice 0.28 mM (128.4 ng/mL) giving i.g. to mice half of the our dose (23) . Another study demonstrated that after giving orally to rats of very high concentrations of EGCG (1120 mg/kg) as a part of green tea epimers mixture (4000 mg/kg) the maximum EGCG level detected in plasma by HPLC with an UV-detector set at 280 nm was 17 mg/mL although the EGCG bioavailability remained low (40) . The authors found that the oral administration of the green tea epimers mixture increased the total antioxidant capacity of rat plasma measured by DPPH free radical assay and the ferricreducing antioxidant power (FRAP) parameter.
We found that the largest portion of the absorbed EGCG in rat plasma was unconjugated. Kim et al. (18) also found that after giving to rats 0.6% GTPP as a drinking fluid, the largest portion of EGCG in plasma was unconjugated. In this characteristic, the rat model of EGCG bioavailability is closer to the human model. For example, after ingesting of green tea solids containing 195 mg EGCG/kg at a dose of 20 mg/kg body weight, which corresponds to 12 cups of regular green tea, at the 1 st hour the free EGCG was 77% from the total and at the 5 th hour -64% (41) . In mice plasma 50 -90% of EGCG was present in the conjugated form (23) .
In humans similar concentrations to the concentrations found by us in rats were achieved after ingesting of EGCG quantity equivalent to [6] [7] [8] (38) . In other report EGCG concentrations in plasma 46 -268 ng/mL at 1 st hour and 40 -300 ng/mL at 4 th hour were reported after ingestion of 1.2 g green tea solid containing 88 mg of EGCG (22) . EGCG was dose-dependently incorporated in human plasma as ingestion of 225, 375 and 525 mg EGCG as a part of green tea extract, which contained also EGC, led to concentrations in human plasma 0.66, 4.3 and 4.4 mM 90 minutes post dose (42) . Ingestion of 400 mg of pure EGCG in humans led to maximum levels in plasma 2 mM at 2 nd hour that decreased to 0.87 mM at 6 th hour (43) . This intake of EGCG increased the total antioxidant parameter (TRAP) about 16 -19% (43) .
Our results referred to the cited data demonstrate that after drinking a regular green tea at doses 6 -8 cups in human plasma could be achieved EGCG concentrations equivalent to concentrations in rat plasma promoting antioxidant activity. In addition, we determined EGCG concentration in rat tissues when EGCG was given at a dose having antioxidant potential in plasma. In small intestine and in colon EGCG concentration was in the range 4.75 -24.4 nmol/g. If we assume that 1 g is equivalent to 1 mL, we receive concentrations of EGCG in the range 4.75 -24.4 mM, which were reported to show anticancer activities in cell culture experiments. For example, in cell intestinal epithelial cell line EGCG with IC 50 > 18 mM inhibited IkB kinase complex activity which mediated activation of the oxidative stress sensitive transcription factor NF-kB (5) . EGCG at IC 50 3 nM and 5 mM inhibited cell transformation in rat tracheal epithelial and human lung tumor cells, respectively (44) .
In kidneys, liver, spleen, lung, brain, prostate, and bladder lower quantities of free EGCG (0.1 -1 nmol/g) were detected. After orally administering EGCG, it first encounters the small intestine and then the liver. Previous studies in rat cell cultures had shown that the rat liver possesses much higher glucuronidase activity than the small intestine (33) . In liver EGCG is largely conjugated before reaching other organs and as a result is excluded from these organs where is found in small quantities. Reasons for the low bioavailability of EGCG are not only its conjugation, but also its oxidation at physiological pH and binding to proteins (28) .
Our results are consistent with results showing the EGCG tissue distribution in rats after drinking 0.6% GTPP for 8 days where the highest concentrations of EGCG were found in the large intestine and esophagus and smaller quantities were found in the other organs (18) . The tissue levels in spleen, lung, prostate, and bladder obtained by these researchers are close to the found by us at 2 nd and 5 th hour after orally administering EGCG at a dose of 150 mg/kg body weight. Interestingly, the EGCG concentrations measured by us in the small intestine, colon, and plasma, are close to the peak levels in mice model where EGCG has been given i.g. at a dose of 75 mg/kg body weight (23) . In brain we detected concentrations of EGCG about 0.2 nmol/g, quantity which could be equivalent to 0.2 mM. Recently Lu et al. (45) have shown that EGCG at IC 50 of 0.2 mM inhibited the methylation of 3, 4 -dihydroxy-L-phenylalanine (L-DOPA), the drug of first choice in the treatment of Parkinson's disease. EGCG, penetrating in the brain, and inhibiting L-DOPA methylation, which facilitates L-DOPA conversion to dopamine, could have a beneficial effect in patients with Parkinson's disease.
Conclusions
We showed that after administering EGCG perorally to rats at a dose of 150 mg/kg body weight the antioxidant activity of rat plasma, measured by the hydrophilic radical initiated oxidation ex vivo, was increased. We determined EGCG plasma levels and tissues distribution at 2 nd and 5 th hours post dose. In rat plasma the EGCG concentrations measured were equivalent to the reached in humans after drinking of 6 -8 cups of regular green tea. In rat small intestine and colon levels of EGCG comparable with the used in cell culture anticancer experiments were obtained. For measuring EGCG concentrations in rat plasma and tissues we developed an HPLC method with electrochemical detector using internal standard. The method elaborated by us could be used also for the measurement of EC and EGC in plasma and tissues.
